Standard BioTools (LAB) Projected to Post Earnings on Monday

Key Points

• Standard BioTools is expected to release its Q2 2025 earnings on August 11th, with analysts forecasting earnings of ($0.04) per share and revenue of $39.83 million.
• AQR Capital Management LLC significantly increased its stake in Standard BioTools by 862.2% during the first quarter, owning 53.74% of the company’s stock after the acquisition.
• TD Cowen has upgraded Standard BioTools' shares to a "strong-buy" rating, indicating positive sentiment among analysts.

Standard BioTools (NASDAQ:LAB - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Standard BioTools to post earnings of ($0.04) per share and revenue of $39.83 million for the quarter.

Standard BioTools Trading Up 1.2%

Shares of LAB stock traded up $0.02 during mid-day trading on Thursday, reaching $1.30. The stock had a trading volume of 324,051 shares, compared to its average volume of 1,774,739. Standard BioTools has a 12-month low of $0.92 and a 12-month high of $2.32. The company has a market cap of $491.87 million, a P/E ratio of -3.70 and a beta of 1.32. The business has a 50-day simple moving average of $1.22 and a 200 day simple moving average of $1.22.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Standard BioTools to a "strong-buy" rating in a report on Thursday, July 17th.

Institutional Investors Weigh In On Standard BioTools

An institutional investor recently raised its position in Standard BioTools stock. AQR Capital Management LLC boosted its position in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 862.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 482,912 shares of the company's stock after buying an additional 432,725 shares during the period. AQR Capital Management LLC owned approximately 0.13% of Standard BioTools worth $522,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 53.74% of the company's stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.